COEPW — Coeptis Therapeutics Holdings Inc
NASDAQ · Healthcare · Biotechnology
Coeptis Therapeutics Holdings Inc (COEPW) is a biotechnology company listed on NASDAQ. It is led by David Mehalick, based in 105 Bradford Road, Wexford, PA, United States, 15090, with about 4 employees. Coeptis Therapeutics Holdings, Inc., a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy. The company has collaboration with Statera BioPharma to develop and commercialize STAT-201 for Crohn's disease; and Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. Coeptis Therapeutics Holdings, Inc. is headquartered in Wexford, Pennsylvania.
Latest reported COEPW revenue for 2025-09-30 was $237.4K. Net income was -$2.9M. Revenue was up 18.3% from 2025-06-30 to 2025-09-30.
Use this COEPW page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the COEPW quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the COEPW SEC filings page. Lician reads the product cache first so this HTML stays unique to Coeptis Therapeutics Holdings Inc even when a live quote feed is slow.
About Coeptis Therapeutics Holdings Inc
Coeptis Therapeutics Holdings, Inc., a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy. The company has collaboration with Statera BioPharma to develop and commercialize STAT-201 for Crohn's disease; and Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. Coeptis Therapeutics Holdings, Inc. is headquartered in Wexford, Pennsylvania.
COEPW Key Statistics
EPS
-$5.65
Revenue
$0.00
Net Income
-$10.88M
Gross Profit
$0.00
Free Cash Flow
$0.00
Employees
4
COEPW Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $75.00K |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$10.88M | -$21.27M | -$37.57M | -$13.45M |
| EPS (Diluted) | -$5.65 | -$16.56 | -$2.63 | -$1.23 |
Total Assets
$8.91M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$532.88K
Operating Cash Flow
-$6.65M
Free Cash Flow
$0.00
Coeptis Therapeutics Holdings Inc Company Information
- Co-Founder, Chairman, CEO & Pres
- David Mehalick
- Headquarters
- 105 Bradford Road, Wexford, PA, United States, 15090
- Website
- coeptispharma.com
- Phone
- 724 934 6467
- IPO / Founded
- 2020-12-17
- Sector
- Healthcare
- Industry
- Biotechnology